Drug Topics

OCTOBER 3, 2024

Senators Ron Wyden and Sherrod Brown wrote a letter to the Federal Trade Commission calling to explore yet another PBM tactic impeding competition.

266

266

Pharmacy Times

OCTOBER 3, 2024

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

144

144

STAT

OCTOBER 3, 2024

Schizophrenia is a poorly understood illness, but scientists now have greater insight into one of the disorder’s hallmarks, auditory hallucinations, thanks to new research published Thursday. People with schizophrenia often “hear” voices and sounds even when there are none — up to 80% of people with the mental illness have auditory hallucinations.

141

141

Drug Topics

OCTOBER 3, 2024

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

Vaccines 138

Vaccines Immunization 138

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

OCTOBER 3, 2024

Nearly 20 years after neuroscientist John Donoghue placed electrodes on Matthew Nagle’s motor cortex , allowing the man with no limb movement to control objects using his thoughts, the brain-computer interface field looks dramatically different — both the people doing the research and the technologies they are creating.  Researchers like Leigh Hochberg and Eddie Chang and big-name startups such as Synchron and Paradromics have turned what was not too long ago an arcane academi

141

141

Pharmacy Times

OCTOBER 3, 2024

As American Pharmacists Month begins, Alan Corley talks the importance of pharmacists and the value of the profession personally and to the overall community.

132

132

Pharmacy Times

OCTOBER 3, 2024

As of now, data suggest minimal risk of drug interactions between oral contraceptives and injectable semaglutide.

132

132

STAT

OCTOBER 3, 2024

UnitedHealth Group is suing the Centers for Medicare and Medicaid Services, asking a judge to halt the federal agency from lowering the insurance company’s 2025 Medicare Advantage quality ratings. The health care giant alleged in the lawsuit that Medicare downgraded its Medicare Advantage star ratings, which are supposed to indicate a plan’s quality, based on “an arbitrary and capricious assessment” of its call center.

Insurance 132

Insurance 132

Pharmacy Times

OCTOBER 3, 2024

Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy.

Chemotherapy 132

Chemotherapy 132

Drug Topics

OCTOBER 3, 2024

The Heart Failure Society of America 2024 Annual Meeting featured presentations exploring the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for patients with heart failure.

Hospitals 131

Hospitals 131

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 3, 2024

Apple Watch may help keep people with Parkinson’s disease out of the hospital. That’s according to early data from a Kaiser Permanente pilot program. Since late 2023, Kaiser Permanente has been giving some of its Parkinson’s patients in California an Apple Watch app called StrivePD, developed by Rune Labs. The app uses the onboard sensors in the device to track tremors associated with the disease; dyskinesia, a side effect of medication; activity; sleep; and falls.

People Management 131

People Management Hospitals 131

IDStewardship

OCTOBER 3, 2024

Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article Posted 30 September 2024 I recently had the honor to give a key note speech for my alma matter, Northeastern University in Boston, MA. It took me a while to put the thoughts together and I had some support from my friend Dr. Robert Kraljevich. It seems like other people might potentially benefit from reading this and learning from my 20 years of experience in the pharmacy biz… so I put it on this webpage!

130

130

Fierce Healthcare

OCTOBER 3, 2024

Providers and suppliers feeling the weight of Hurricane Helene and its aftermath will see accelerated and advance Medicare payments, alongside other assistances and flexibilities, the Centers for M | CMS said it wants to head off “significant cash flow issues from the unusual circumstances impacting facilities’ operations.” It is also offering other flexibilities around debt repayments.

128

128

Fierce Pharma

OCTOBER 3, 2024

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

Compounding Pharmacies 124

Compounding Pharmacies Compounding 124

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

OCTOBER 3, 2024

Another significant legal headache related to star ratings is on the table of the federal government just days before open enrollment begins. | One call center interaction is at the crux of a lawsuit UnitedHealthcare is bringing forward against the federal government because of a reduced star rating score.

125

125

Fierce Pharma

OCTOBER 3, 2024

Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C (NPC) community, Zevra Therapeutics is confident that its new drug Miplyff | Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C community, Zevra Therapeutics is confident that its new drug Miplyffa can become the “foundation and the cornerstone” for treatment of the debilitating rare disease going forwar

124

124

Fierce Healthcare

OCTOBER 3, 2024

Four of the nation’s leading cancer centers are coming together to work on AI through a newly formed collaborative, the Cancer AI Alliance (CAIA). | Four leading cancer centers are leveraging their data resources and AI to gain ground on cancer.

125

125

Pharmacy Times

OCTOBER 3, 2024

Currently, Danon disease has a poor prognosis and does not have any pharmaceutical therapeutics for treatment or management.

FDA 123

FDA 123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Pharma

OCTOBER 3, 2024

On its way to becoming the most highly anticipated approval of 2024, BMS’ schizophrenia treatment Cobenfy has had an unusual but instructive odyssey.

122

122

Pharmacy Times

OCTOBER 3, 2024

Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.

123

123

Fierce Healthcare

OCTOBER 3, 2024

The state of Texas is accusing major pharmacy benefit managers and drug companies of colluding to raise the cost of insulin. | Texas is suing drug manufacturers and the big three PBMs for insulin pricing tactics that adversely impacted the state's diabetes patients.

120

120

Fierce Pharma

OCTOBER 3, 2024

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an

FDA 119

FDA 119

STAT

OCTOBER 3, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. This week Medicare regulators released a 79-page report on a pandemic-era home hospital program that allowed approved health systems to deliver inpatient care in people’s homes.

Hospitals 119

Hospitals 119

Drug Topics

OCTOBER 3, 2024

See what’s trending in pharmacy with a preview of the Drug Topics September/October issue.

112

112

pharmaphorum

OCTOBER 3, 2024

Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.

111

111

Drug Topics

OCTOBER 3, 2024

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

112

112

pharmaphorum

OCTOBER 3, 2024

Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.

111

111

STAT

OCTOBER 3, 2024

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. When it comes to delivering shareholder value through M&A, Ron Renaud is a biotech investor’s best friend. Over the last 10 years, all three of the companies he has helmed were sold to Big Pharma for a combined $16 billion.

108

108

Fierce Healthcare

OCTOBER 3, 2024

Smaller healthcare organizations, such as regional hospitals, nursing homes, rehab centers and clinics, are not immune from cyberattacks and data breaches. | Smaller healthcare organizations, such as regional hospitals, nursing homes, rehab centers and clinics, are not immune from cyberattacks and data breaches. They’re attractive targets to hackers, especially those launching ransomware attacks, because attackers know how critical their systems are to providing care and they often lack robust c

Nursing Homes 106

Nursing Homes Immunization Hospitals 106

Pharmaceutical Technology

OCTOBER 3, 2024

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.

105

105

Fierce Pharma

OCTOBER 3, 2024

As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing (PDF) o | As officials consider how to distribute Eli Lilly’s Mounjaro to a nation that has a rapidly growing obesity problem, England’s National Health Service is proposing that those who need it most should get it first.

105

105

pharmaphorum

OCTOBER 3, 2024

A new report commissioned by ABPI found hospitals engaging in industry partnerships more likely to follow NICE recommendations.

Hospitals 105

Hospitals 105

Fierce Pharma

OCTOBER 3, 2024

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly weighing sales of certain units and facilities. | WuXi AppTec has put its cell and gene therapy manufacturing arm, WuXi Advanced Therapies, on the market, The Financial Times reported Thursday. At the same time, WuXi Biologics is working with advisors to gauge interest in some of its European production facilities, the news outlet added, citing sources.

105

105